Advertisement

Medical Management of Ulcerative Colitis

  • Paul Flanagan
  • Keith Leiper
Chapter

Abstract

Ulcerative colitis (UC) affects about 1 in 400 of the UK population, with a stable incidence in the last few decades. The peak age of onset of disease is around 30 years, but onset of disease can occur at any age, though it is rare after 70 years [1]. The strongest risk factor for developing UC is a family history of inflammatory bowel disease (IBD) (either UC or Crohn’s disease); however, the risk of monozygotic twins developing UC is lower than for Crohn’s disease (10% versus 38%) broadly suggesting that UC is less “genetic” than CD [1].

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Ulcerative Colitis Patient Oral Steroid Toxic Megacolon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Stange EF, Travis SPL, Vermeire S. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Moser G. How often do patients with IBD have symptom recurrence? Inflamm Bowel Dis. 2008;14 Suppl 2:S47. Erratum in: Inflamm Bowel Dis. 2009;15:1438–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut. 2000;46 Suppl 1:i1–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci. 2010;55:2002–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126–37.PubMedCrossRefGoogle Scholar
  7. 7.
    Rahier JF, Yazdanpanah Y, Colombel JF, Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut. 2009;58:1313–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009;30:614–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(3):CD005112Google Scholar
  11. 11.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005;353:2462–76.Google Scholar
  12. 12.
    Ulcerative colitis (subacute manifestations)- infliximab. 2010. www.nice.org.uk/nicemedia/pdf/TA140Guidance
  13. 13.
    Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Hart AL, Ng SC. Review article: the optimal medical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2010;32:615–27.PubMedGoogle Scholar
  17. 17.
    Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Link 5ZRoyal Liverpool University HospitalLiverpoolUK

Personalised recommendations